Accessibility Menu
Orgenesis logo

Orgenesis(OTC) ORGS

Current Price$0.40
Market Cap$3.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)+6%
5 Year-99%
1 Year-60%
1 Month-19%
Orgenesis last closing stock price
MetricPriceDate
Last closeUSD 0.402026-07-23
Orgenesis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+39,900%USD 0.002026-07-16
1 month-19.19%USD 0.502026-06-23
3 month-30.43%USD 0.582026-04-24
Year to date+166.67%USD 0.152025-12-31
1 year-60%USD 1.002025-07-23
3 year-96.19%USD 10.502023-07-24
5 year-99.22%USD 51.202021-07-23
Since inception+6.09%USD 0.382010-07-28

Orgenesis Financials at a Glance

Market Cap

$3.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

-$12.87M

Net Income (TTM)

-$43.94M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

248.93 (High)

Price

$0.40

Volume

200

Open

$0.04

Previous Close

$0.40

Daily Range

$0.04 - $0.40

52-Week Range

$0.00 - $1.00

Estimated Earnings Date

Aug 7, 2026

ORGS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Orgenesis

Orgenesis develops cell and gene therapies for hospitals and clinics. Its platforms help doctors treat patients using their own or donor cells. These solutions aim to make advanced therapies more accessible and affordable for healthcare providers.

Products and Services

  • Cell Process Development Services: Customizes cell therapy production for hospitals; 98.6% of 2024 revenue.
  • Hospital Services: Provides on-site support for therapy processing and compliance; included in main revenue stream.
  • License Fees: Out-licenses therapy and manufacturing rights; 1.4% of 2024 revenue.
  • Decentralized Cell Processing Platform: Automated systems for producing therapies near patients; targets hospitals and research centers.
  • Therapy Pipeline: Includes treatments for cancer, metabolic, and viral diseases; serves clinical trial partners and hospitals.

Growth and Expansion

  • Acquired full ownership of Octomera LLC in January 2024.
  • Purchased assets from Broaden Bioscience (CAR-T processing) and Theracell (cell therapy platforms) in 2024.
  • Formed collaborations with Germfree (mobile processing units) and universities like Columbia University and UC Davis in 2024.
  • Expanded global activities to North America, Europe, Asia, the Middle East, and Australia since 2012.
  • Liquidated subsidiaries in Korea, Israel, Australia, and Belgium in 2024 to streamline operations.

What Makes Orgenesis Stand Out

Orgenesis uses a decentralized production model, allowing therapies to be made near patients. Its automated systems aim to lower costs and simplify logistics for hospitals. The company partners globally to adapt therapies for local needs and regulations.

Five Things You Need to Know

  • Revenue was $1.035 million in 2024, up 95% from 2023.
  • Operating loss was $39.77 million in 2024, improved from 2023.
  • Top three US customers made up 91% of 2024 revenue.
  • Cash was $0.1 million at year-end 2024, with $65.8 million debt.
  • Company faces substantial doubt about its ability to continue operating.

Bottom Line

Orgenesis has shifted to a decentralized, hospital-focused model for cell therapy production. The company faces major financial challenges but continues to adapt its business and partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

77

CEO

Vered Caplan

Website

www.orgenesis.com

Headquarters

Germantown, MD 20876, US

ORGS Financials

Key Financial Metrics (TTM)

Gross Margin

-1080.19%

Operating Margin

-10120.00%

Net Income Margin

-10445.47%

Return on Equity

-1683.22%

Return on Capital

-3274.48%

Return on Assets

-380.44%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

9.80M

Volume

200

Avg. Volume

1.04K

Financials (TTM)

Gross Profit

-$18.37M

Operating Income

-$93.26M

EBITDA

-$68.24M

Operating Cash Flow

-$15.48M

Capital Expenditure

-$318.00K

Free Cash Flow

-$15.80M

Cash & ST Invst.

$204.00K

Total Debt

$17.30M

Orgenesis Performance Analysis

Orgenesis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 35,502,000N/A
20222022-12-31USD 36,025,0001.5%
20232023-12-31USD 530,000-98.5%
20242024-12-31USD 1,035,00095.3%
Orgenesis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31-12462.7%
Q12024-03-31101.0%
Q22024-06-3074.5%
Q32024-09-3041.1%
Orgenesis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -7.44N/A
20222022-12-31USD -5.93-20.2%
20232023-12-31USD -19.08221.7%
20242024-12-31USD -11.44-40.1%
Orgenesis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31-586.0%
Q12024-03-3186.1%
Q22024-06-3020.7%
Q32024-09-3017.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$347.00K

+215.5%

Gross Profit

-$238.00K

-720.7%

Gross Margin

-68.59%

N/A

Market Cap

$3.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$50.91K

N/A

Employees

77

N/A

Net Income

$9.12M

+344.8%

EBITDA

-$7.66M

-203.0%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$204.00K

+270.9%

Total Debt

$17.30M

-20.5%

Accounts Receivable

$1.40M

+24.4%

Inventory

$0.00

-100.0%

Long Term Debt

$10.10M

-45.5%

Short Term Debt

$7.19M

+124.3%

Return on Assets

-3.80%

N/A

Return on Invested Capital

28.91%

N/A

Free Cash Flow

-$4.69M

-216.5%

Operating Cash Flow

-$4.63M

-292.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EMMAEmmaus Life Sciences, Inc.
$0.01+0.00%
SQZBSQZ Biotechnologies Company
$0.02+0.00%
PAIOFPaion AG
$0.07+0.00%
HXBMHelix BioMedix, Inc.
$1.79+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%

Questions About ORGS

What is the current price of Orgenesis?

Orgenesis is trading at $0.40 per share.

What is the 52-week range for Orgenesis?

Over the past 52 weeks, Orgenesis has traded between $0.00 and $1.00.

How much debt does Orgenesis have?

As of the most recent reporting period, Orgenesis reported total debt of $18.26M.

How much cash does Orgenesis have on hand?

Orgenesis reported $687.00K in cash and cash equivalents in its most recent financial results.

What is Orgenesis’s dividend yield?

Orgenesis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services